-
公开(公告)号：US20240293566A1
公开(公告)日：2024-09-05
申请号：US18572930
申请日：2022-06-21
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Frank DELFINO , Marcus KELLY , Jessica KIRSHNER , Thomas NITTOLI , Gavin THURSTON
CPC classification number: A61K47/68035 , A61K45/06 , A61K47/6849 , A61P35/00
Abstract: The present disclosure provides antibody-drug conjugates (ADCs) comprising antibodies that bind to the class III variant of EGFR (EGFRVIII) conjugated to tesirine, and methods of using the same. According to certain embodiments, the antibodies or antigen-binding fragments thereof, useful herein, bind human EGFRVIII with high affinity. The antibodies or antigen-binding fragments thereof, useful herein, may be fully human antibodies. The ADCs provided herein are useful for the treatment of various cancers.
-
公开(公告)号：US20210147557A1
公开(公告)日：2021-05-20
申请号：US16918656
申请日：2020-07-01
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K47/68 , C07K16/30
Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
-
公开(公告)号：US20180312594A1
公开(公告)日：2018-11-01
申请号：US16033477
申请日：2018-07-12
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
-
公开(公告)号：US20240226163A1
公开(公告)日：2024-07-11
申请号：US18559009
申请日：2022-05-03
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Kevin BRAY , Frank DELFINO , David DILILLO
CPC classification number: A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464486 , A61P35/00 , C07K14/7051 , C07K16/2809 , C07K16/30 , A61K2239/13 , A61K2239/28 , A61K2239/29 , C07K2317/31 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/03
Abstract: MAGE-A4, or Melanoma-Associated Antigen A4, is a cancer-testis antigen (CTA) on the X chromosome. The present disclosure provides MAGE-A4-specific chimeric antigen receptors, cells expressing such chimeric antigen receptors, and MAGE-A4 specific isolated antibodies. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present disclosure are capable of inhibiting the growth of tumors expressing MAGE-A4. The engineered cells of the present disclosure are useful for the treatment of diseases and disorders in which an upregulated or induced MAGE-A4-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the MAGE-A4-specific chimeric antigen receptors of the present disclosure are useful for the treatment of various cancers.
-
Patent Agency Ranking
5.发明公开公开(公告)号：US20230330254A1
公开(公告)日：2023-10-19
申请号：US18182323
申请日：2023-03-11
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Haruka OKAMOTO , Jean YANOLATOS , AMY HAN , Xiang ZHENG , William OLSON , Andrew J. MURPHY , Frank DELFINO
CPC classification number: A61K47/6849 , A61K47/6811 , A61K47/545 , A61P3/10 , A61K2039/505
Abstract: The present invention provides antibody-tethered drug conjugates (ATDCs) and compositions thereof that are useful, for example, for targeting glucagon-like peptide 1 receptor (GLP1R) and treating various conditions, e.g., diabetes. Methods for making such ATDCs are also provided along with method of use thereof.
-
公开(公告)号：US20170007715A1
公开(公告)日：2017-01-12
申请号：US15202822
申请日：2016-07-06
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Julian ANDREEV , Nithya THAMBI , Frank DELFINO , Joel MARTIN , Gavin THURSTON , Katherine CYGNAR , Nicholas PAPADOPOULOS
CPC classification number: A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6879 , A61K2039/507 , A61K2039/572 , A61P35/00 , C07K14/4702 , C07K16/1203 , C07K16/18 , C07K16/22 , C07K16/28 , C07K16/2833 , C07K16/2866 , C07K16/2869 , C07K16/2896 , C07K16/30 , C07K16/32 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/76 , C07K2317/77 , C07K2319/00 , C07K2319/30 , C12N9/6454
Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
Abstract translation: 本发明提供多特异性抗原结合分子及其用途。 多特异性抗原结合分子包含特异性结合靶分子的第一抗原结合结构域和特异性结合内在效应蛋白的第二抗原结合结构域。 在一些实施方案中，本发明的多特异性抗原结合分子可以是能够结合靶分子和内化效应蛋白的双特异性抗体。 在本发明的某些实施方案中，通过本发明的多特异性抗原结合分子同时结合靶分子和内化效应蛋白导致目标分子的活性比所述靶分子的结合更大程度地减弱 靶分子单独。 在本发明的其它实施方案中，靶分子是肿瘤相关抗原，并且通过本发明的多特异性抗原结合分子同时结合肿瘤相关抗原和内在效应蛋白导致或促进靶向杀伤肿瘤细胞 。
-
公开(公告)号：US20230042324A1
公开(公告)日：2023-02-09
申请号：US17812256
申请日：2022-07-13
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Frank DELFINO , Dimitris SKOKOS , Bei WANG
IPC: C07K16/28 , A61K39/395 , A61K45/06
Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR) and methods of using the same, including, e.g., methods of treatment using the same.
-
公开(公告)号：US20160304615A1
公开(公告)日：2016-10-20
申请号：US15170628
申请日：2016-06-01
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
IPC: C07K16/28 , A61K39/395 , A61K45/06 , C07K16/30 , A61K47/48
CPC classification number: C07K16/2863 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3069 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
-
公开(公告)号：US20150259423A1
公开(公告)日：2015-09-17
申请号：US14643886
申请日：2015-03-10
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K47/48
CPC classification number: C07K16/2863 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3069 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
Abstract translation: 本发明提供了结合EGFR（EGFRvIII）的III类变体的抗体及其使用方法。 根据某些实施方案，本发明的抗体以高亲和力结合人EGFRvIII。 本发明的抗体可以是完全人抗体。 本发明包括与细胞毒性剂，放射性核素或对细胞生长或增殖有害的其它部分缀合的抗EGFRvIII抗体。 本发明的抗体可用于治疗各种癌症。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.019 seconds)
